» Articles » PMID: 15869600

Altered Cytoskeleton Organization in Platelets from Patients with MYH9-related Disease

Overview
Publisher Elsevier
Specialty Hematology
Date 2005 May 5
PMID 15869600
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

MYH9-related disease (MYH9-RD) is an autosomal dominant disorder deriving from mutations in the MYH9 gene encoding for the heavy chain of non-muscle myosin IIA, and characterized by thrombocytopenia and giant platelets. Isoform IIA of myosin is the only one expressed in platelets, but the possibility that MYH9 mutations affect the organization of contractile structures in these blood elements has never been investigated. In this work we have analyzed the composition and the agonist-induced reorganization of the platelet cytoskeleton from seven MYH9-RD patients belonging to four different families. We found that an increased amount of myosin was constitutively associated with actin in the cytoskeleton of resting MYH9-RD platelets. Upon platelet stimulation, an impaired increase in the total cytoskeletal proteins was observed. Moreover, selected membrane glycoproteins, tyrosine kinases, and small GTPases failed to interact with the cytoskeleton in agonist-stimulated MYH9-RD platelets. These results demonstrate for the first time that mutations of MYH9 result in an alteration of the composition and agonist-induced reorganization of the platelet cytoskeleton. We suggest that these abnormalities may represent the biochemical basis for the previously reported functional alterations of MYH9-RD platelets, and for the abnormal platelet formation from megakaryocytes, resulting in thrombocytopenia and giant platelets.

Citing Articles

Non-Muscle Myosin II A: Friend or Foe in Cancer?.

Feroz W, Park B, Siripurapu M, Ntim N, Kilroy M, Sheikh A Int J Mol Sci. 2024; 25(17).

PMID: 39273383 PMC: 11395477. DOI: 10.3390/ijms25179435.


Reduced platelet forces underlie impaired hemostasis in mouse models of -related disease.

Baumann J, Sachs L, Otto O, Schoen I, Nestler P, Zaninetti C Sci Adv. 2022; 8(20):eabn2627.

PMID: 35584211 PMC: 9116608. DOI: 10.1126/sciadv.abn2627.


Ex vivo anticoagulants affect human blood platelet biomechanics with implications for high-throughput functional mechanophenotyping.

Sachs L, Wesche J, Lenkeit L, Greinacher A, Bender M, Otto O Commun Biol. 2022; 5(1):86.

PMID: 35064207 PMC: 8782918. DOI: 10.1038/s42003-021-02982-6.


Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease.

Pal K, Nowak R, Billington N, Liu R, Ghosh A, Sellers J Blood. 2020; 135(21):1887-1898.

PMID: 32315395 PMC: 7243143. DOI: 10.1182/blood.2019003064.


Phosphoglycerol dihydroceramide, a distinctive ceramide produced by Porphyromonas gingivalis, promotes RANKL-induced osteoclastogenesis by acting on non-muscle myosin II-A (Myh9), an osteoclast cell fusion regulatory factor.

Kanzaki H, Movila A, Kayal R, Napimoga M, Egashira K, Dewhirst F Biochim Biophys Acta Mol Cell Biol Lipids. 2017; 1862(5):452-462.

PMID: 28153611 PMC: 5663505. DOI: 10.1016/j.bbalip.2017.01.008.